Labs are preparing for the next vaccination campaign against bronchiolitis. Pfizer and Sanofi, both of which are expected to market a vaccine against the respiratory syncytial virus, are still awaiting approval from the authorities.
Each winter, nearly 30% of babies under the age of two, or 480,000 infants, contract broncholitis. In 2% to 3% of cases, the illness is so severe that it requires hospitalization. In 2022-2023, the triple epidemic of bronchiolaitis, flu and covid caused severe congestion in emergency services.